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Recently, we identified neuregulin 1 (NRG1) as a susceptibility gene for schizophrenia in the Icelandic population,
by a combined linkage and association approach. Here, we report the first study evaluating the relevance of NRG1
to schizophrenia in a population outside Iceland. Markers representing a core at-risk haplotype found in Icelanders
at the 5′ end of the NRG1 gene were genotyped in 609 unrelated Scottish patients and 618 unrelated Scottish
control individuals. This haplotype consisted of five SNP markers and two microsatellites, which all appear to be
in strong linkage disequilibrium. For the Scottish patients and control subjects, haplotype frequencies were estimated
by maximum likelihood, using the expectation-maximization algorithm. The frequency of the seven-marker hap-
lotype among the Scottish patients was significantly greater than that among the control subjects (10.2% vs. 5.9%,
). The estimated risk ratio was 1.8, which is in keeping with our report of unrelated Icelandic patientsPp .00031
(2.1). Three of the seven markers in the haplotype gave single-point P values ranging from .000064 to .0021 for
the allele contributing to the at-risk haplotype. This direct replication of haplotype association in a second population
further implicates NRG1 as a factor that contributes to the etiology of schizophrenia.
Introduction
Consistent association has not been found between
schizophrenia (MIM 181500) and variants of the many
candidate genes tested (O’Donovan and Owen 1999).
Here, we present an association study, in which we
searched for a haplotype, in the neuregulin 1 gene
(NRG1 [MIM 142445]), that increases the risk of
schizophrenia in Iceland (Stefansson et al. 2002). The
gene was identified through a genomewide linkage scan,
of 33 large extended families with schizophrenia, that
pointed to a locus on chromosome 8p. Extensive fine-
mapping of the 8p locus and haplotype association anal-
ysis of 478 patients with schizophrenia and 394 control
individuals narrowed the region of interest to the 5′ end
of the large gene. A haplotype made up of several mark-
ers within a block of linkage disequilibrium showed sig-
nificant association with an estimated relative risk of 2.2
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(one-sided P values of .0000067–.000087). This core
haplotype covers 290 kb and contains the first 5′ exon
of NRG1, encoding the amino terminus of glial growth
factor 2 (GGF2), and upstream sequences.
Linkage to chromosome 8p (SCZD6 [MIM 603013])
has been reported by a number of research groups (Pul-
ver et al. 1995; Kendler et al. 1996; Levinson et al. 1996;
Blouin et al. 1998; Kaufmann et al. 1998; Shaw et al.
1998; Brzustowicz et al. 1999; Gurling et al. 2001;
DeLisi et al. 2002; Straub et al. 2002).
Icelanders are thought to be of Norse and Gaelic an-
cestry (Pa´lsson and Edwards 1972; Steffensen 1975;
Helgason et al. 2001). The linkage results in the Irish
population (Kendler et al. 1996; Straub et al. 2002)
point to the 8p region are therefore particularly inter-
esting, although the reported intervals in these studies
appear to be 10–30 cM telomeric to the interval re-
ported in the Icelandic study. Chromosome 8 has been
one of the more problematic chromosomes in terms of
sequence assembly and marker orders and has been fur-
ther complicated by inversion polymorphisms (Giglio
et al. 2001) and deletions (Yu et al. 2002). This may,
in part, explain the differences in the intervals reported,
or there may be a second schizophrenia gene on chro-
mosome 8p.
Here, we present results of haplotype analysis that con-
firms the presence in a Scottish population of the same
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Table 1













Seven-marker haplotype 5.9 (618) 10.2 (609) .00031 1.8 7.6 (394) 14.4 (402) .000087 2.1
Five-marker SNP 27.4 (593) 35.4 (596) .000032 1.5 25.1 (394) 32.1 (402) .0018 1.4
SNP8NRG221132 G (2) 89.4 (526) 90.9 (574) .13 1.2 88.0 (252) 90.0 (366) .14 1.2
SNP8NRG221533 C (1) 30.6 (515) 38.4 (573) .000064 1.4 29.7 (386) 36.4 (370) .0028 1.4
SNP8NRG241930 G (2) 60.9 (561) 66.6 (577) .0021 1.3 65.7 (315) 68.3 (367) .16 1.1
SNP8NRG243177 T (3) 35.8 (514) 42.4 (568) .00080 1.3 33.3 (108) 38.9 (321) .069 1.3
SNP8NRG433E1006 G (2) 88.4 (290) 89.2 (301) .34 1.1 85.5 (259) 87.3 (366) .18 1.2
478B14-848 0 31.8 (588) 32.8 (596) .30 1.1 35.9 (294) 37.5 (340) .27 1.1
420M9-1395 0 41.2 (541) 42.5 (587) .27 1.1 45.3 (290) 47.3 (350) .24 1.1
a Numeric values for SNP alleles shown within parenthesis are the same as those given in Stefansson et al. 2002.
b Number of genotyped individuals for each marker is given in parenthesis.
seven-marker at-risk haplotype found in Iceland. The at-
risk haplotype was found in significant excess in the Scot-
tish patients ( ), with a risk ratio of 1.8.Pp .00031
Subjects and Methods
Patients with Schizophrenia
Unrelated patients with schizophrenia ( ) werenp 609
all recruited from the Scottish population, were of Eu-
ropean ancestry, and met Diagnostic and Statistical
Manual of Mental Disorders, Third Edition, Revised
(DSM- III-R ) criteria (American Psychiatric Association
1987) for schizophrenia or schizoaffective disorder. Di-
agnosis was based on psychiatric case note inspection
and, when appropriate, through the use of the lifetime
version of the Schizophrenia and Affective Disorders
Schedule (Spitzer and Endicott 1977). Diagnosis was
confirmed by consensus of two senior psychiatrists. Con-
trol individuals ( ) were drawn from the samenp 618
population and were ethnically matched. Informed con-
sent was obtained from all patients and control individ-
uals. DNA samples were coded to create and preserve
anonymity, and genotyping was performed by persons
who were blind to diagnostic status of the samples. This
study was approved by the Scottish Multiregional Ethics
Committee.
Estimation of Haplotype Frequencies
and Determination of Statistical Significance
In the present study, we genotyped unrelated patients
and control individuals but no relatives. To handle miss-
ing genotypes and the lack of familial information to
derive the phase, we applied our own implementation
of a likelihood approach, using the expectation-maxi-
mization (EM) algorithm (Dempster et al. 1977) as a
computational tool, to estimate the haplotype frequen-
cies. Under the null hypothesis, the affected and control
individuals are assumed to have identical frequencies of
all haplotypes. Under the alternative hypothesis, the can-
didate at-risk haplotype is allowed to have a higher fre-
quency in affected than in control individuals, whereas
the ratios of the frequencies of all other haplotypes are
assumed to be the same in both groups. Likelihoods are
maximized separately under both hypotheses, and cor-
responding 1-df likelihood-ratio statistics are used to
evaluate statistical significance. Our own computer pro-
gram was developed to fit our chosen models—and to
handle missing genotypes and haplotypes with many
markers efficiently; however, our use of the EM algo-
rithm is very similar to methods used by others (Excoffier
and Slatkin 1995; Hawley and Kidd 1995; Long et al.
1995). Although applied in a slightly different setting,
the 1-df model we use is essentially that used by Clayton
and Jones (1999). The method used here is identical to
that reported elsewhere, and the data in table 1 for the
Icelandic population are exactly the same as those re-
ported in the same article (Stefansson et al. 2002).
SNP Genotyping
Four SNPs (SNP8NRG221132, SNP8NRG221533,
SNP8NRG241930, and SNP8NRG243177) were scored
using a method based on template-directed primer ex-
tension and detection by fluorescence polarization (FP)
(Chen et al. 1999). Amplimers can be found on the de-
CODE Genetics Web site, and detailed sequence infor-
mation is available through GenBank (accession number
AF491780; third-party annotation [TPA] BK000383).
The SNP in the 5′ exon of GGF2, SNP8NRG433-
E1006, was scored by sequencing 163 bp of the exon.
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This exon is very GC rich, and SNP genotyping with
the use of the FP assay described above has proved dif-
ficult in our hands for this polymorphism. Nested PCR
was performed to obtain product for direct sequencing.
The first amplification reaction was done using prim-
ers CCTACCCCTGCACCCCCAATAAATAAA and
CTTCCTGTCGAGTGCCCCCTGCT. The reaction vol-
ume was 10 ml, and, for each PCR, 30 ng of genomic
DNA was amplified in the presence of 3.5 pmol of each
primer, 0.25 U AmpliTaq Gold, 0.2 mM dNTPs, 10%
dimethyl sulfoxide, and 2.5 mM MgCl2 (buffer was sup-
plied by the manufacturer). Cycling conditions were
95C for 10 min, followed by 40 cycles at 94C for 15
s, annealing at 68C for 30 s, and extension at 72C for
1 min. The second reaction was performed using the
same concentration of inner primers, TGCCACTAC-
TGCTGCTGCT and ACCTTTCCCTCGATCACCAC.
Except for the addition of 1 ml of the first amplification
reaction, as a template, to 9 ml of the mixture, conditions
were the same as in the first amplification reaction de-
scribed above. Cycling conditions for the second am-
plification step were 95C for 10 min, followed by 35
cycles at 94C for 15 s, annealing at 58C for 30 s, and
extension at 72C for 1 min. The PCR product was
sequenced by direct sequencing after cleaning the PCR
product by use of a BigDye Terminator Cycle Sequencing
kit (PE Biosystems). The inner primers were used for the
cycle-sequencing reaction, and fragments were separated
by electrophoresis on ABI 3700 instruments (Applied
Biosystems).
Microsatellite Genotyping
Microsatellite markers were genotyped as described
by Gretarsdottir et al. (2002). Amplimers for micro-
satellites 478B14-848 and 420M9-1395 can be found
on the deCODE Genetics Web site, and detailed se-
quence information is available through GenBank (ac-
cession number AF491780; TPA BK000383). Allele 0,
in table 1, for markers 478B14-848 and 420M9-1395
refers to PCR-product sizes of 219 bp and 274 bp,
respectively.
Results
In the present haplotype association analysis, we deter-
mined whether a given haplotype among the Scottish
patients was in excess of that found in control individ-
uals; therefore, unless otherwise stated,P values reported
for association tests are one sided and without adjust-
ment for multiple comparison. All case and control sub-
jects in the present study were independent, and likeli-
hoods were therefore computed while treating all
affected individuals as independent.
A seven-marker core haplotype consisting of 5 SNPs
and two microsatellite markers was previously found in
excess in Icelandic patients (Stefansson et al. 2002). In
table 1, the data for unrelated Icelandic patients and
control individuals are shown in comparison with the
data for unrelated Scottish patients and control indi-
viduals. We have now genotyped the seven markers that
constitute the at-risk haplotype in 609 Scottish patients
and 618 Scottish control individuals. The estimated fre-
quency of the at-risk haplotype was higher in the Scot-
tish patients than in the Scottish control individuals,
which is in keeping with what was found in the Icelandic
population. The estimated haplotype frequency was
10.2% in the Scottish patients and 5.9% in Scottish
control individuals, giving a risk ratio of 1.8 (table 1).
Carrier frequencies are thus 19.4% and 11.5%, re-
spectively, assuming a multiplicative model. Further-
more, alleles for three of the seven markers—including
SNP8NRG221533, which also showed significant sin-
gle-marker association in the Icelandic population (table
1)—in the haplotype were in significant excess in the
Scottish patients with schizophrenia.
The patients with schizophrenia were recruited from
a broader geographical area of Scotland than were the
control subjects, who were drawn from the city of Ab-
erdeen and five surrounding counties and from the Glas-
gow region. However, we compared the haplotype fre-
quencies in patients from different areas and found no
differences. This suggests that population stratification
is not a likely explanation for the observed differences.
Also noted is that the issue of multiple comparisons is
not a serious concern here, because five of the nine tests
produce significant results, and four are significant after
Bonferroni adjustment, including the seven-marker at-
risk haplotype and allele C for SNP8NRG221533, both
of which were in significant excess in the Icelandic pop-
ulation (table 1).
Discussion
The NRG1 gene was originally identified as a suscepti-
bility gene for schizophrenia by using a combination of
a linkage and association approaches based on microsat-
ellite markers and then using SNPs after microsatellite at-
risk haplotypes were identified. SNP haplotypes are, in
general, more stable and may capture an ancestral hap-
lotype better than microsatellite haplotypes do, but the
microsatellite markers are more cost-effective and infor-
mative when screening regions for association. Further-
more, the microsatellites may be better suited than SNPs
to the capture of more-recent haplotypes and mutations.
The strength of the present study is that we are directly
testing seven alleles that constitute one at-risk haplotype.
Complications and problems related to multiple testing
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are avoided. Transmission/disequlibrium tests can be
helpful to avoid population stratification. In the Icelandic
study, we reported transmission/disequilibrium data for
the at-risk haplotype that were also supportive, although
data were available for only a limited number of patients
because of the lack of complete triad data. In the present
case-control study, we found no evidence for stratification
when we compared the frequency of the at-risk haplotype
in patients from different areas within Scotland. Al-
though the possibility of bias due to stratification cannot
be completely eliminated, we are heartened by the fact
that not only are the results with the Scottish sample
statistically significant but the frequencies of alleles/hap-
lotypes and estimated relative risks are all very similar
to the Icelandic sample.
Although the present study and our previous one
show that the seven-marker haplotype is significantly
associated with schizophrenia in both Iceland and Scot-
land, they do not reveal the underlying functional var-
iation. Given that the haplotype overrides the first pro-
moter (among several) of NRG1 and the first exon of
GGF2, it is possible that the corresponding functional
variation affects the expression or splicing of the GGF2
isoform. The SNP, SNP8NRG433E1006, is in the first
exon of GGF2. The SNP allele contributing to the at-
risk haplotype was not found in significant excess in
patients, relative to control individuals, and it is there-
fore unlikely to represent the functional variation. The
associations of three other SNPs typed within the hap-
lotype were as significant as that of the overriding hap-
lotype in the Scottish samples. However, in both the
Icelandic and the Scottish samples, the estimated relative
risks of the individual SNPs were less than the relative
risk of the seven-marker haplotype, leading us to con-
clude that none of the individual SNPs can fully account
for the underlying functional variation. The discrepancy
between statistical significance and estimated relative
risk may be explained as follows: The haplotype and
the individual SNPs all have incomplete association
with the underlying functional variant. As surrogates
for the functional at-risk variant, the haplotype, which
is rarer and more specific, produces fewer false positives
but more false negatives than do the individual SNPs.
In previous work, we and others have shown that
mouse mutants for either NRG1 or its receptor, ErbB4,
show stereotypic behavioral abnormalities that are
similar to those exhibited by normal mice treated
with the psychogenic drug phencyclidine (Gerlai et al.
2000; Stefansson et al. 2002). We also showed that
brains of Nrg1 mutant mice had fewer functional N-
methyl D-aspartate (NMDA) receptors than did wild-
type mice (Stefansson et al. 2002).
One of the roles that NRG1 plays in the adult CNS
is the regulation, in certain neurons, of the expression
and phosphorylation of certain neurotransmitter-recep-
tor subunits and their related complexes, in an activity-
dependent manner (Ozaki et al. 1997; Rieff et al. 1999;
Garcia et al. 2000; Cameron et al. 2001). NRG1 does
not appear to be restricted to a single neurotransmitter
system; rather, it appears to play a role in NMDA and
acetylcholine, as well as g-aminobutyric acid–receptor,
regulation, at least in certain neuronal systems (Fisch-
bach and Rosen 1997; Ozaki et al. 1997; Rieff et al.
1999; Cameron et al. 2001). Therefore,NRG1 provides
a way of unifying a large body of evidence, coming from
many directions, that suggests that multiple neurotrans-
mitter systems and their receptors are involved in
schizophrenia by representing a common denominator
upstream of neurotransmitter expression and activa-
tion. Furthermore, NRG1 may provide support for the
view that schizophrenia is caused by dysregulation of
synaptic plasticity in the adult. These new data from a
separate outbred white population closely replicate the
findings from the Icelandic population and provide
strong additional evidence for involvement of NRG1 as
a genetic risk factor for schizophrenia.
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